The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury
Abstract
OBJECTIVES: The long-term outcomes of patients with drug induced liver injury (DILI) are not well described. The aim of this study was to determine the frequency and severity of persistent liver biochemistry abnormalities in DILI patients followed over 2 years. METHODS: Subjects with evidence of liver injury at 6 months after DILI onset were offered a month 12 and 24 study visit. RESULTS: Amongst the 99 patients with definite, probable, or very likely DILI and available laboratory data at 12 months after DILI onset, 74 (75%) had persistent liver injury (persisters) defined as a serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 × upper limit of normal (ULN) or an alkaline phosphatase >ULN, while 25 (25%) had resolved liver injury (resolvers). On multivariate analysis, month 12 persisters were significantly older (52.6 vs. 43.7 years, P=0.01) and more likely to have a cholestatic lab profile at DILI onset (54 vs. 20%, P<0.01) than resolvers. The month 12 persisters also had significantly poorer SF-36 physical summary scores at DILI onset and throughout follow-up compared with the resolvers (P<0.01). Amongst the 17 subjects with a liver biopsy obtained at a median of 387 days after DILI onset, 9 had chronic cholestasis, 3 had steatohepatitis, and 3 had chronic hepatitis. CONCLUSIONS: In all, 75% of subjects with liver injury at 6 months after DILI onset have laboratory evidence of persistent liver injury during prolonged follow-up. Higher serum alkaline phosphatase levels at presentation and older patient age were independent predictors of persistent liver injury. Subjects with persistent liver injury at 12 months after DILI onset should be carefully monitored and assessed for liver disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The incidence of chronic DILI in 598 subjects enrolled into the DILIN was 21% at 6 months, with African Americans and patients with a cholestatic liver injury at presentation being at increased risk.147”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Andrade, R. J., Lucena, I. M., Kaplowitz, N., García-Muņoz, B., Borraz, Y., Pachkoria, K., García-Cortés, M., Fernández, C. M., Pelaez, G., Rodrigo, L., et al. (2006) · Hepatology · doi:10.1002/hep.21424 · Cited by 309
Ductular reactions in human liver: Diversity at the interface
Gouw, A. S. H., Clouston, A. D., & Theise, N. D. (2011) · Hepatology · doi:10.1002/hep.24613 · Cited by 275
Research works printed but not linked: 26
- Ostapowicz, 2002, Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States., Ann Intern Med, 137, 947, 10.7326/0003-4819-137-12-200212170-00007 · DOI · Paper page
- Fontana, 2014, Idiosyncratic drug induced liver injury is associated with substantial morbidity and mortality within 6 months from onset., Gastroenterology, 147, 96, 10.1053/j.gastro.2014.03.045 · DOI · Paper page
- Chalasani, 2008, Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States., Gastroenterology, 135, 1924, 10.1053/j.gastro.2008.09.011 · DOI · Paper page
- Aithal, 1999, The natural history of histologically proved drug-induced liver disease., Gut, 44, 731, 10.1136/gut.44.5.731 · DOI · Paper page
- Bjornsson, 2009, The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice., J Hepatol, 50, 511, 10.1016/j.jhep.2008.10.021 · DOI · Paper page
- Bjornosson, 2007, Long-term follow-up of patients with mild to moderate drug-induced liver injury., Aliment Pharmacol Ther, 26, 79, 10.1111/j.1365-2036.2007.03355.x · DOI
- Fontana, 2009, Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct., Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
- Rockey, 2010, Rochon J et al. for the US DILIN. Causality assessment in drug induced liver injury using a structured expert opinion process: comparison to RUCAM., Hepatology, 51, 2117, 10.1002/hep.23577 · DOI · Paper page
- Ware, 1999, Health-related quality of life in chronic hepatitis C: impact of disease and treatment response., Hepatology, 30, 264, 10.1002/hep.510300203 · DOI · Paper page
- Kleiner, 2014, Hepatic histological findings in suspected drug-Induced liver injury: systematic evaluation and clinical associations., Hepatology, 59, 661, 10.1002/hep.26709 · DOI · Paper page
- Williams, 2011, Prevalence of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study., Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038 · DOI · Paper page
- Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity., Hepatology, 40, 1387, 10.1002/hep.20466 · DOI · Paper page
- Fontana, 2014, 2-year outcomes in initial survivors with acute liver failure: results from a prospective, multicenter study., Liver Int, 35, 370, 10.1111/liv.12632 · DOI
- Wiese, 2000, Low frequency of cirrhosis in a hepatitis C (genotype 1b) single source outbreak in Germany: a 20 year multicenter study., Hepatology, 32, 91, 10.1053/jhep.2000.8169 · DOI · Paper page
- Seeff, 2001, Long-term morbidity and mortality of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood institute Collaborative Study., Hepatology, 33, 455, 10.1053/jhep.2001.21905 · DOI · Paper page
- Feng, 2006, Characteristics associated with liver graft failure: the concept of a donor risk index., Am J Transplant, 6, 783, 10.1111/j.1600-6143.2006.01242.x · DOI · Paper page
- Yamasahiki, 2012, Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey., Liver Transpl, 18, 1069, 10.1002/lt.23469 · DOI
- Fontana, 2013, Aging promotes the development of diet induced murine steatohepatitis but not steatosis., Hepatology, 57, 995, 10.1002/hep.26099 · DOI
- Levy, 2003, Drug-induced cholestasis., Clin Liv Dis, 7, 311, 10.1016/S1089-3261(03)00032-1 · DOI
- Mandapoor, 1994, Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis., Hepatology, 20, 1437, 10.1002/hep.1840200610 · DOI
- Davies, 1994, Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis., J Hepatol, 20, 112, 10.1016/S0168-8278(05)80476-3 · DOI
- Saxena, 2002, Destruction of canals of hering in primary biliary cirrhosis., Hum Pathol, 33, 983, 10.1053/hupa.2002.128060 · DOI
- Khan, 2013, Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: minimal change PBC?, Hepatology, 57, 700, 10.1002/hep.26020 · DOI
- Bedossa, 2003, Sampling variability of liver fibrosis in chronic hepatitis C., Hepatology, 38, 1449, 10.1053/jhep.2003.09022 · DOI · Paper page
- Bjornsson, 2010, Drug-induced autoimmune hepatitis: clinical characteristics and prognosis., Hepatology, 51, 2040, 10.1002/hep.23588 · DOI · Paper page
- Czaja, 2011, Drug-induced autoimmune-like hepatitis., Dig Dis Sci, 56, 958, 10.1007/s10620-011-1611-4 · DOI · Paper page
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationAASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Self-citationDrug induced liver injury: an update
Garcia-Cortes, M., Robles-Diaz, M., Stephens, C., Ortega-Alonso, A., Lucena, M. I., & Andrade, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02885-1 · Cited by 286
Church, R. J., Kullak‐Ublick, G. A., Aubrecht, J., Bonkovsky, H. L., Chalasani, N., Fontana, R. J., Goepfert, J. C., Hackman, F., King, N. M. P., Kirby, S., et al. (2019) · Hepatology · doi:10.1002/hep.29802 · Cited by 231
Self-citation
Metadata
- Authors
- Fontana, R. J., Hayashi, P. H., Barnhart, H., Kleiner, D. E., Reddy, R. K., Chalasani, N., Lee, W. M., Stolz, A., Phillips, T., Serrano, J., & Watkins, P. B.
- Venue
- American Journal of Gastroenterology
- Published
- 2015-10
- Volume
- 110
- Issue
- 10
- Pages
- 1450-1459
- ISSN
- 0002-9270
- Cited by
- 101
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury. https://app.cochat.ai/papers/10.1038/ajg.2015.283
- The paper
- Fontana, R. J., Hayashi, P. H., Barnhart, H., Kleiner, D. E., Reddy, R. K., Chalasani, N., Lee, W. M., Stolz, A., Phillips, T., Serrano, J., & Watkins, P. B. (2015). Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2015.283
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.